First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
The company is making its entry into the Hyderabad market through its unique asset-light business model
Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi
ASG is accelerating its doctor-led mission to enhance the quality of care, deliver eye care for all, and improve quality of life across India.
Value chain collaboration aims to foster a circular ecosystem and reduce the carbon footprint of single-use surgical instruments molded in Ixef PARA.
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
Subscribe To Our Newsletter & Stay Updated
